Odevixibat (A4250) for the Treatment of Progressive Familial Intrahepatic Cholestasis (Expanded Access Program)
Latest Information Update: 11 Mar 2024
At a glance
- Drugs Odevixibat (Primary)
- Indications Intrahepatic cholestasis
- Focus Expanded access; Therapeutic Use
- Sponsors Albireo Pharma
- 22 Jul 2020 New trial record
- 20 Jul 2020 According to an Albireo Pharma media release, the company is working closely with local regulators in other countries to offer access.